Pharmalink is a Stockholm, Sweden-based specialty pharma company focused on developing Nefecon for primary IgA nephropathy (IgAN). Nefecon is a potential disease-modifying treatment for patients with primary IgAN at risk of developing end-stage renal disease. The company raised SEK100m (€10.5m/US$12m) in mezzanine financing to prepare a Phase 3 clinical development program for Nefecon. Backers included existing investors Investinor and Industrifonden. Pharmalink, led by Managing Director Johan Häggblad, plans to pursue an initial public offering on Nasdaq Stockholm in 2016, pending favourable market conditions. The IPO is intended primarily to fund clinical development toward market approval and commercialization in key territories. Pharmalink AB is a specialty pharmaceutical company based in Stockholm focused on developing high-value products for niche indications. The company is advancing clinical programs including Busulipo™, a conditioning agent for hematopoietic stem cell transplantation (HSCT), and Nefecon, a potential disease-modifying treatment for primary IgA nephropathy. Pharmalink plans to use newly raised funds to prepare for pivotal studies with Busulipo™ and to advance the product toward market approval. The company will also complete the pivotal Phase IIb study with Nefecon. Management is seeking commercial partners for products outside the Nordic region and is open to in-licensing or acquiring additional opportunities for commercialization in the Nordic market. Johan Häggblad is listed as Managing Director, and the company is actively pursuing niche and hospital care indications. Pharmalink is a Stockholm, Sweden–based specialty pharmaceutical company focused on developing two lead product candidates, Nefecon and Busulipo. Nefecon is being developed for patients with IgA nephropathy and the company is preparing pivotal clinical trials for that program. Busulipo is being developed as a conditioning agent prior to hematopoietic stem cell transplantation; Pharmalink is preparing for late‑stage clinical trials and for registration and introduction into key global markets. The company raised SEK 35m in funding to advance these two programs. Pharmalink is led by Managing Director Johan Häggblad and is also actively in‑licensing promising new projects to expand its pipeline. The fundraising was supported by existing shareholders, including Industrifonden.

Total raised

$29M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Oct 2015